We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cheng Fong Chemical received a warning letter from the FDA for dirty equipment, poorly maintained facilities and improper investigations into possibly tainted batches of active pharmaceutical ingredients. Read More
A federal appeals court rejected Genzyme’s rehearing request in a lawsuit that alleges the Patent Trial and Appeal Board violated protocol when it invalidated the company’s patent covering treatment methods for a rare muscle disease. Read More
The Center for American Progress has unveiled a plan to create a system for health care payers to negotiate prices based on the clinical benefits of a treatment. Read More
The FDA has rejected Pain Therapeutics extended-release oxycodone Remoxy for the third time, issuing a complete response letter that hinges on the agency’s request for new studies to substantiate the product’s abuse-deterrence label claims. Read More